Guardant Health, Inc. (GH)
Health Care · life sciences tools & diagnostics · NASDAQ
Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
What Guardant Health, Inc. does
Guardant Health is a precision oncology company that develops and provides blood-based and tissue-based genomic testing to help manage cancer patients throughout all stages of the disease. The company offers a portfolio of liquid biopsy products that provide comprehensive genomic profiling and cancer screening, enabling clinicians to make more informed treatment decisions.
Themes: precision oncology, liquid biopsy, genomics, cancer screening, NGS-based diagnostics
Fundamentals
- Price$170.92 as of 2026-08-26 close
- Market cap$22.9B as of 2026-08-26
- 1-year return+169.5% 2025-08-26 close $63.43 → 2026-08-26 close $170.92
- P/En/a negative earnings
- Net margin-38.3% as of 2026-08-26
- Gross margin+65.0% as of 2026-08-26
- ROE-246.6% as of 2026-08-26
- Debt / equity16.78 as of 2026-08-26
- Revenue growth (YoY)+42.7% as of 2026-08-26
- Revenue CAGR (3y)+29.8% SEC XBRL
- Beta1.28 as of 2026-08-26
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How GH compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-26
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
GH is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no valuation data.
Short-term score
59.8 #205 of 1,696 scored · #48 of 239 in Health Care
Trend 77th: a "golden cross" — its 50-day average is above its 200-day; momentum 66th: over the past 3 months this stock beat the market by 35.9 percentage points; weakest is volume and participation 17th: trading volume is about normal versus its 30-day average.
Scores as of 25 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How Guardant Health, Inc. looks technically
Guardant Health, Inc. (GH) is trading 49.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 434 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is 3.2% below its 52-week high (its highest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 49.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +49.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $155.30 | $155.30 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $114.54 | $114.54 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 155. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 434 trading days ago — a "golden cross", a bullish long-term signal | 434 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with buyers in control | 29.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 60, neither overbought (above 70) nor oversold (below 30) | 60.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($155.00 to $173.17) — its "stochastic" reading is 88 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 87.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $176.58 | $176.58 |
|---|---|---|
| From the 52-week high | it is 3.2% below its 52-week high (its highest price of the past year) | -3.2% |
| Above the 52-week low | it is 220.1% above its 52-week low (its lowest price of the past year) | +220.1% |
| Below the 52-week high | it is 3.2% below its highest point of the past year | 3.2% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $181.07 (set on 2021-02-12) | $181.07 |
| Given back of the 52-week move | over the past year its closes ranged ($54.79 to $170.92), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $95.44 to $99.15. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 5.6% below its all-time high | -5.6% |
| Nearest price level | it is trading 1.2% below a resistance level at $173.00 — a price it turned at twice since 2026-07-06, most recently on 2026-08-10. Since 2024-08-26 it has 11 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.2% |
| All-time low | its lowest closing price on record is $15.81 (set on 2024-04-19) | $15.81 |
| Above the all-time low | it is 981.1% above its all-time low | +981.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.76 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.76 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $153.65 and $172.26 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $153.65 – $162.95 – $172.26 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 7.3 daily ranges above its 200-day average price (49.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.95× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Open gap | it gapped 6.7% above the previous close 18 sessions ago and has not traded back through the level it left behind at 152.35 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.7% |
| Gap filled | a 3.5% gap down opened on 2026-08-24 has been "filled" today — price traded back through the level the gap left behind, and it took 2 sessions to close | today |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.74% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.3 percentage points (the stock gained 16.0% while the market gained 3.7%) | +12.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 40.5 percentage points (the stock gained 42.6% while the market gained 2.1%) | +40.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 63.3 percentage points (the stock gained 74.5% while the market gained 11.1%) | +63.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 150.7 percentage points (the stock gained 169.5% while the market gained 18.7%) | +150.7% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 13.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +11.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 41% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $121.41 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP. | +40.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $162.54 — a volume-weighted average of daily closes over 20 sessions, not a true tick-by-tick VWAP. | +5.2% |
Price levels it has turned at before
GH last closed at $170.92 on 2026-08-26. Since 2024-08-26 it has turned at 11 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $173.00 | Resistance | 1.2% above the last close | turned there twice · 2026-07-06 to 2026-08-10 |
| $134.49 | Support | 21.3% below the last close | turned there twice · 2026-05-29 to 2026-06-15 |
| $113.11 | Support | 33.8% below the last close | turned there twice · 2025-11-25 to 2026-02-20 |
| $101.15 | Support | 40.8% below the last close | turned there twice · 2025-11-10 to 2026-05-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $155.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $190.72 and $212.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $155.00.
This reading has stood for 3 trading days, since 2026-08-24.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.32 mean, 1=Strong Buy…5=Strong Sell) — 24 analysts
- Mean price target$194.29 range $105.00 – $225.00; median $195.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GH
- Consensus EPS estimate-$0.3018 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Continued operating losses and need for additional capital to fund operations.","Intense competition and potential for rapid technological obsolescence.","Regulatory risks associated with the development, approval, and commercialization of diagnostic products."]
What changed in the latest 10-Q
AI-assisted comparison of GH's 10-Q filed 2026-05-07 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to Annual Report on Form 10-K for year ended December 31, 2025 (newer filing) vs. December 31, 2024 (older filing)
- Added description that Smart Platform 'utilizes methylation technology with genomic, epigenomic, and RNA-based data, to unlock multi-modal biology with proprietary chemistry, advanced algorithms and our InfinityAI learning engine'
- Added that GuardantINFINITY blood test is 'powered by our Smart Platform'
- Added description of 'AI analytics' to company's transformation approach
- Added that Guardant Reveal test has been 'expanded to include late-stage therapy response monitoring for patients with solid tumors'
- Added that Shield MCD test has been 'launched in multiple markets in Asia'
- Added language about 'marketable securities' to cash position description (newer: '$1.2 billion' in 'cash, cash equivalents, restricted cash and marketable securities'; older: '$689.5 million' in 'cash, cash equivalents and restricted cash')
- Added revenue and loss figures for Q1 2026: '$301.7 million' revenue and '$112.1 million' net loss vs. Q1 2025 comparative figures of '$203.5 million' and '$95.2 million'
- Added 'cost of revenue' language to testing volume factor discussion
- Removed:
- Removed reference to 'formerly known as the Guardant360 LDT test' for Guardant360 Liquid test
- Removed specific mention of colorectal cancer from Guardant360 CDx companion diagnostic applications (older mentioned 'non-small cell lung cancer, or NSCLC, and breast cancer'; newer mentions 'NSCLC, colorectal cancer and breast cancer' – actually this is an addition, not removal)
- Removed mention of 'Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging'
- Removed detailed timeline of Shield development: references to May 2022 launch as LDT, December 2022 ECLIPSE study results, March 2023 PMA submission, July 2024 FDA approval, August 2024 commercial availability, June 2025 NCCN inclusion, October 2025 MCD results report expansion
- Removed specific historical context and dates related to Shield regulatory and commercial milestones
- Removed nine-month revenue and loss figures (older filing included nine-month data: '$700.8 million' revenue and '$287.8 million' net loss for nine months ended September 30, 2025)
- Reworded:
- Changed 'and real-world data' to 'real-world data and AI analytics'
- Changed 'helping doctors select the best treatment' to 'treatment selection'
- Changed 'Guardant Reveal blood test' to 'Guardant Reveal test' (removed 'blood')
- Changed description of GuardantINFINITY from 'a next-generation Smart Liquid Biopsy' to 'powered by our Smart Platform'
- Changed 'Using data collected from our tests' to 'Using data collected from our tests and through AI-enabled analytical tools'
- Changed 'Our revenue and costs are affected' to 'Our revenue and cost of revenue are affected'
- Simplified Shield description from detailed regulatory/commercial timeline to streamlined current state description
- Notes:
- The older filing text appears truncated at the end of the payer coverage section, limiting full comparison of that section
- Newer filing reports Q1 2026 results (three months ended March 31, 2026) while older filing reports Q3 2025 results (three months ended September 30, 2025), making direct operational comparisons across different periods
Risk Factors
- Added:
- Forward-looking statements reference changed from 'Annual Report on Form 10-K for the year ended December 31, 2024' (older filing) to 'Annual Report on Form 10-K for the year ended December 31, 2025' (newer filing)
- Reworded:
- Balance sheet dates changed from September 30, 2025 and December 31, 2024 (older) to March 31, 2026 and December 31, 2025 (newer)
- Short-term marketable securities line item changed from 'Short-term marketable debt securities' (older) to 'Short-term marketable securities' (newer)
- Stockholders' equity presentation changed from 'Stockholders' Equity (Deficit)' table header (older) to 'Stockholders' Deficit' (newer)
- Statement of stockholders' changes changed from showing July 1, 2025 opening balance (older) to January 1, 2026 opening balance (newer)
- Comparison period for operations statements changed from 'Three Months Ended September 30' and 'Nine Months Ended September 30' (older) to 'Three Months Ended March 31' (newer)
- Notes:
- The two filings appear to be from different quarterly reporting periods (Q3 2025 in older filing vs. Q1 2026 in newer filing), making direct financial comparisons not directly applicable to the Risk Factors section itself
- The text provided consists primarily of financial statements and forward-looking statements boilerplate rather than the actual Risk Factors disclosure content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 31 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 4 sells ($3M) — 2 selling insiders
- Last 90 days1 buy ($78456) · 31 sells ($59M) — 1 buying, 10 selling insiders
- Last 180 days1 buy ($78456) · 56 sells ($94M) — 1 buying, 12 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
7 institutional 13F filers reported holding GH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 20,330,327
- Reported value $1,877,912,349
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GH had 11,416,103 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
GH had 8.51% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.39 days to cover at the same settlement.
- Reported short interest (shares) 11,416,103
- Short interest (% of shares outstanding) 8.51%
- Prior settlement (shares) 11,421,015
- Reported change -0.04%
- Days to cover (reported) 5.39
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Exact Sciences (EXAS)
- Illumina (ILMN)
- Roche (RHHBY)
- Thermo Fisher Scientific (TMO)
- Natera (NTRA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GH vs…
Guardant Health, Inc. is found in…
Frequently asked questions
What does Guardant Health, Inc. (GH) do?
Guardant Health is a precision oncology company that develops and provides blood-based and tissue-based genomic testing to help manage cancer patients throughout all stages of the disease. The company offers a portfolio of liquid biopsy products that provide comprehensive genomic profiling and cancer screening, enabling clinicians to make more informed treatment decisions.
What sector is Guardant Health, Inc. (GH) in?
Guardant Health, Inc. (GH) is classified in the Health Care sector. Its industry is life sciences tools & diagnostics. It trades on NASDAQ.
Who are Guardant Health, Inc.'s (GH) competitors?
Notable peers of Guardant Health, Inc. (GH) include Exact Sciences, Illumina, Roche, Thermo Fisher Scientific and Natera. This peer set is informational only — not financial advice.
Is Guardant Health, Inc. (GH) overbought or oversold right now?
Guardant Health, Inc. (GH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 60, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GH come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.